MetaCap

NovoCure Limited (NVCR)

NASDAQ: NVCRHealth CareMedical/Dental InstrumentsUSD

10.71+0.02 (+0.19%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

NVCR stock chart

Technical analysis

Key statistics

All statistics
EPS (TTM)
-$1.06
52-week range
9.82 – 21.45
Day range
10.61 – 11.06
Volume / Avg
1.64M / 1.51M
Beta
—

52-week range

$9.82$21.45

NVCR stock today

Shares of NovoCure (NVCR) finished higher on Nov 20 at $10.71, a gain of 0.19% or $0.02 per share, versus the S&P 500's 3.70% decline. Shares are 50.1% below their 52-week high of $21.45, set on Jul 24, 2026 and 9.1% above the 52-week low of $9.82, near the bottom of the past year's range. NVCR is down 17.2% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 10.4%.

NovoCure has posted a net loss over the last twelve months (EPS of -$1.06), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About NovoCure

Company profile

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. Its TTFields devices include Optune Gio, Optune Lua, and Optune Pax. The company also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer.

Industry
Medical/Dental Instruments
CEO
Mr. Frank Leonard
Headquarters
Baar
Employees
1,605
IPO year
2015

Financial highlights

Full financials

In fiscal 2025, NovoCure generated $655.4 million in revenue, up 8.3% from fiscal 2024, its 2nd consecutive year of revenue growth. NovoCure reported a net loss of $136.2 million, compared with a loss of $168.6 million a year earlier. Gross margin was 74.5% (down from 77.3%) and operating margin -23.5%.

NovoCure annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$655.35M$605.22M$509.34M$537.84M$535.03M
Growth+8.28%+18.82%-5.30%+0.53%+8.23%
Net income$-136.23M$-168.63M$-207.04M$-92.53M$-58.35M
EPS (diluted)$-1.22$-1.56$-1.95$-0.88$-0.56

Analyst forecast

Forecast

Consensus (7 analysts)

buy

Avg. price target

$26.14+144.07%

  • Strong buy 1
  • Buy 3
  • Hold 3
  • Sell 0
  • Strong sell 0

Target range

Low $15.00High $52.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Oct 29, 2026
EPS actual vs est.
$-0.09 vs $-0.21
Surprise
+57.14%

NVCR news

All NVCR news

NovoCure peers

Health Care sector
NVCR peer companies
CompanyPrice% ChgMarket capCompare
TNDMTandem Diabetes Care Inc.17.46+3.93%$1.22Bvs NVCR
DRTSAlpha Tau Medical Ltd.11.76+3.93%$1.09Bvs NVCR
PRCTPROCEPT BioRobotics Corporation24.70-4.08%$1.42Bvs NVCR
SIBNSI-BONE Inc.23.73-0.08%$1.07Bvs NVCR
IRMDiRadimed Corporation81.02-0.30%$1.04Bvs NVCR
IARTIntegra LifeSciences Holdings Corporation13.25-2.21%$1.03Bvs NVCR
ATECAlphatec Holdings Inc.6.68-3.19%$1.02Bvs NVCR
SGPSpyGlass Pharma Inc.30.43-1.14%$1.02Bvs NVCR

Indexes, lists and sector

NovoCure stock FAQ

What is NovoCure's stock price today?

NVCR last traded at $10.71 as of Nov 20, 4:00 PM EST, up 0.19% on the day. Prices are delayed at least 15 minutes.

Who is NovoCure's CEO?

Mr. Frank Leonard is the chief executive officer of NovoCure Limited, which has about 1,605 employees.

What is the NVCR 52-week high?

The 52-week high for NVCR is $21.45 and the 52-week low is $9.82. The stock is currently 50.1% below its high.

Compare NVCR